Pedro Milanez-Almeida

5PUBLICATIONS
33CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Comparative language studiesInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

|Mar 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma.

Fredrik Schjesvold, Andrew Spencer, Yael C Cohen

|Dec 19, 2022
Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.

Qin Xu, Pedro Milanez-Almeida, Andrew J Martins

|Mar 30, 2022
Robust, persistent adaptive immune responses to SARS-CoV-2 in the oropharyngeal lymphoid tissue of children.

Qin Xu, Pedro Milanez-Almeida, Andrew J Martins

|Feb 12, 2020
Cancer prognosis with shallow tumor RNA sequencing.

Pedro Milanez-Almeida, Andrew J Martins, Ronald N Germain

Pageof 1

Frequent Collaborators

3 joint publications

Ronald N Germain

2 joint publications

Qin Xu

2 joint publications

Andrew J Martins

2 joint publications

Andrea J Radtke